Literature DB >> 6861128

Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines.

G P Wheeler, B J Bowdon, C Temple, D J Adamson, J Webster.   

Abstract

The effects of a number of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) upon the proliferation and the mitotic index of cultured L1210 cells and upon the survival of mice bearing P388 leukemia were determined. The 1,2-dihydrostructure and amino groups or masked amino groups at positions 5 and 7 were necessary for activity, and various substituents at positions 2 and 3 had considerable influence upon the activity. A number of these pyrazines had significant activity against i.p. P388 leukemia in mice, and several pyrazines were more active than the corresponding oxazines or thiazines in both the in vitro and the in vivo systems. The effects of the pyrazines upon the cultured cells were reversible, and the rate and degree of reversibility were influenced by the substituents at positions 2 and 3. Tests performed with two of the pyrazines yielded results that indicate that these compounds, like the known agent nocodazole, might compete with colchicine for binding to tubulin. Synergistic killing of cultured L1210 cells was obtained with combinations of one of the pyrazines and vincristine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861128

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Authors:  W R Waud; S D Harrison; C G Temple; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  CI-980 in advanced melanoma and hormone refractory prostate cancer.

Authors:  C W Ryan; K L Shulman; J M Richards; J W Kugler; J A Sosman; R H Ansari; E E Vokes; N J Vogelzang
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

4.  Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.

Authors:  R P Whitehead; J M Unger; L E Flaherty; J R Eckardt; S A Taylor; M S Didolkar; W Samlowski; V K Sondak
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.

Authors:  S R Patel; M A Burgess; N E Papadopolous; G Sidhu; R Gray; C Plager; J Jenkins; R S Benjamin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.